IMC Chicago’s MoonLake Immunotherapeutics MLTX Stock Holding History
Bought
Maintained
Sold
Other funds holding MLTX
IMC Chicago's MLTX Position: Q3 2026 in Review
IMC Chicago sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2026, closing a stake of 23,048 shares — an estimated $377K sold.
IMC Chicago first reported a position in MLTX in Q4 2025 and held it in 3 quarters. The position peaked at $481K in Q4 2025. 170 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.
- IMC Chicago reported no remaining MoonLake Immunotherapeutics position as of Q3 2026 after selling out during the quarter.
- IMC Chicago sold 23,048 MoonLake Immunotherapeutics shares in Q3 2026, an estimated $377K.
- IMC Chicago first reported a position in MoonLake Immunotherapeutics in Q4 2025 and held it in 3 quarters.
- IMC Chicago's MoonLake Immunotherapeutics position peaked at $481K in Q4 2025.
- 170 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.
Based on IMC Chicago's 13F filing for Q3 2026, filed 5 Nov 2026.